Latest news with #Insulet
Business Insider
15 hours ago
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: Insulet (PODD), Sarepta Therapeutics (SRPT) and Eli Lilly & Co (LLY)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Insulet (PODD – Research Report), Sarepta Therapeutics (SRPT – Research Report) and Eli Lilly & Co (LLY – Research Report) with bullish sentiments. Confident Investing Starts Here: Insulet (PODD) In a report released yesterday, Robbie Marcus from J.P. Morgan maintained a Buy rating on Insulet. The company's shares closed last Friday at $303.15. According to Marcus is a 4-star analyst with an average return of 9.1% and a 52.8% success rate. Marcus covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Bausch + Lomb Corporation, and Inspire Medical Systems. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Insulet with a $337.56 average price target, a 10.9% upside from current levels. In a report issued on June 16, Truist Financial also initiated coverage with a Buy rating on the stock with a $365.00 price target. See Insiders' Hot Stocks on TipRanks >> Sarepta Therapeutics (SRPT) In a report issued on June 20, Anupam Rama from J.P. Morgan maintained a Buy rating on Sarepta Therapeutics, with a price target of $30.00. The company's shares closed last Friday at $20.08. According to Rama has 0 stars on 0-5 stars ranking scale with an average return of -6.9% and a 37.7% success rate. Rama covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Ultragenyx Pharmaceutical, and Kiniksa Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sarepta Therapeutics with a $44.96 average price target, implying an 115.4% upside from current levels. In a report issued on June 5, Scotiabank also upgraded the stock to Buy with a $80.00 price target. Eli Lilly & Co (LLY) Bernstein analyst Courtney Breen maintained a Buy rating on Eli Lilly & Co yesterday and set a price target of $1100.00. The company's shares closed last Friday at $762.73. According to Breen is a 2-star analyst with an average return of 0.5% and a 33.3% success rate. Breen covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Gilead Sciences, and Merck & Company. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Eli Lilly & Co with a $999.57 average price target, implying a 27.2% upside from current levels. In a report issued on June 6, Bank of America Securities also maintained a Buy rating on the stock with a $1000.00 price target.
Yahoo
4 days ago
- Business
- Yahoo
Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod® 5 on Improved Health Outcomes at the American Diabetes Association 85th Scientific Sessions
Presentations and panel discussions to provide deeper dives into the clinical outcomes from Insulet's groundbreaking SECURE-T2D and RADIANT trials Real-world evidence around glycemic outcomes from more than 23,000 people with type 2 diabetes using Omnipod 5 in the United States will also be shared Booth activities include podcasts, hands-on demonstrations led by clinical experts, and immersive experiences, including a comic book featuring a new hero with type 1 diabetes ACTON, Mass., June 19, 2025--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its planned activities during the American Diabetes Association (ADA) 85th Scientific Sessions taking place June 20 – 23, 2025 at the McCormick Place Convention Center in Chicago, Illinois. "We are thrilled to share more details that dive deeper into the clinical outcomes from our groundbreaking SECURE-T2D and RADIANT trials, as well as the real-world outcomes we are seeing, especially with type 2 diabetes," said Dr. Trang Ly, MBBS, FRACP, PhD, Insulet Senior Vice President and Chief Medical Officer. "We are also looking forward to many conversations with healthcare providers about what the outcomes mean, with practical insights on how to optimize therapy." Insulet shared results of the first large pivotal trial of Automated Insulin Delivery (AID) in type 2 diabetes (SECURE-T2D) at last year's ADA conference. In March, Insulet presented results of the first randomized controlled trial to assess the direct transition from multiple daily injections (MDI) to AID in adults and children with type 1 diabetes not meeting glycemic targets with injections (RADIANT). Presentations at ADA this week will provide richer insights into both trials and more. Conference Activities: Dr. Ly will lead a panel discussion, "Setting the Standard with Omnipod 5: Remarkable Results with Unmatched Simplicity," on Sunday, June 22 from 10:15 – 11:00 AM CT in the conference product theater. She will be joined by Dr. Anders L. Carlson, MD, Associate Executive Director, International Diabetes Center, Director, HealthPartners Diabetes Program, and Associate Professor, University of Minnesota Medical School; Dr. Gregory Forlenza, MD, MS, Associate Professor of Pediatrics, Director of Pediatric Diabetes Technology Research, Barbara Davis Center for Diabetes at the University of Colorado Anschutz Medical Campus; and Dr. Emma Wilmot, MB ChB BSc (hons), PhD, FRCP, Associate Professor, University of Nottingham, Honorary Consultant Diabetologist, University Hospitals of Derby and Burton NHS Trust, Royal Derby Hospital UK. They will have an interactive conversation around several thought-provoking case studies designed to challenge conventional thinking and therapeutic approaches. Dr. Ly will also provide a high-level overview of Insulet's innovation roadmap. Additionally, on Saturday, June 21, there will be a Diabetes Learning Byte session, "Go Beyond GLP-1 Therapy in Type 2 Diabetes with Omnipod 5," from 11:00 AM – 11:20 AM CT at booth 927 with Davida F. Kruger, MSN, APN-BC, BC-ADM, Certified Nurse Practitioner, Henry Ford Health Division of Endocrinology, Diabetes, Bone and Mineral Disease; and Leslie Barrett, MS, RD, CDCES, Director of Medical Affairs, Insulet. Oral Presentations Friday, June 20, Session: 5:30 – 6:30 PM CT, Presentation 5:45 – 6:00 PM CT (W184A-D) 130-OR– Real-World Glycemic Outcomes in Adults with Type 2 Diabetes (T2D) Using the Omnipod 5 Automated Insulin Delivery (AID) System with Dr. Sean Oser Saturday, June 21, Session: 1:30 – 3:00 PM CT, Presentation 2:00 – 2:15 PM CT (W185A-D) 155-OR– Reduced Perceived Diabetes Distress with the Omnipod 5 Automated Insulin Delivery (AID) System in Adults with Type 2 Diabetes (T2D) – Analysis of the SECURE-T2D Study with Dr. Kristin Castorino Monday, June 23, Session: 1:30 – 3:00 PM CT, Presentation 2:45 – 3:00 PM CT (W183A) 314-OR– Improved Outcomes Across Baseline Time-in-Range Levels with the Omnipod 5 AID System Compared with Multiple Daily Injections (MDI) in Type 1 Diabetes (T1D): Analysis of the RADIANT Study with Dr. Emma Wilmot Poster Presentations The following poster presentations will be held from 12:30 – 1:30 PM CT in the Poster Hall (Hall F1) during the weekend. Saturday, June 21 [945-P] – Improved Glycemic Outcomes with the Omnipod 5 AID System in Adults with Type 2 Diabetes (T2D) Previously Using Basal without Bolus Insulin: Sub-analysis of the SECURE-T2D Study with Dr. Anders Carlson [937-P] – Successful Transition from Multiple Daily Injections (MDI) to Automated Insulin Delivery (AID): Real-world Glycemic Outcomes among People with Diabetes Using the Omnipod AID System with Dr. Grazia Aleppo [958-P] – Impact of Insulin Therapy Technology on Health-Related Quality of Life in Adults with Type 1 Diabetes: A Health Utility Study of Five Forms of Therapy with Colin Hopley, MPH, Insulet Sunday, June 22 [2011-LB] – iPhone App Adoption Improves Bolusing Frequency in Adolescents and Young Adults with Type 1 Diabetes (T1D): Insights from Real-World Omnipod® 5 Automated Insulin Delivery (AID) System Use with Dr. Gregory Forlenza Booth Activities: Podcast recordings for Beyond the Bolus, Within Range will be conducted from Insulet's booth (1218). Also, a Baird hosted webcast, "ADA Recap Interview with Dr. Trang Ly," will be facilitated by Sr. Research Analyst, Jeff Johnson. This will take place on Monday, June 23, at 11:00 AM CT. The interview will feature a recap of highlights, new clinical data, and updates from ADA. A link to the webcast will be available on the Investor Relations section of the Company's website at under "Events and Presentations," and will be archived for future replay. Insulet will bring immersive booth experiences that showcase how Omnipod 5 is transforming diabetes management. Attendees can engage in hands-on demonstrations led by clinical experts, exploring optimization techniques that support better outcomes. Attendees can also play an educational trivia game to learn how Omnipod 5 brings a whole new level of simplicity and convenience for mealtime insulin dosing. Insulet will also be distributing a new comic book to celebrate representation for the diabetes community. Dyasonic: Sound of Strength featuring a hero with type 1 diabetes. To access the comic book and related materials go to About Insulet Corporation: Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit: and ©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. All other trademarks are the property of their respective owners. The use of third-party trademarks does not constitute an endorsement or imply a relationship or other affiliation. View source version on Contacts Investor Relations: June LazaroffSenior Director, Investor Relations(978) 600-7717jlazaroff@ Media: Angela Geryak WiczekSenior Director, Corporate Communications(978) 932-0611awiczek@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
4 days ago
- Health
- Business Wire
Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod ® 5 on Improved Health Outcomes at the American Diabetes Association 85th Scientific Sessions
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced its planned activities during the American Diabetes Association (ADA) 85 th Scientific Sessions taking place June 20 – 23, 2025 at the McCormick Place Convention Center in Chicago, Illinois. 'We are thrilled to share more details that dive deeper into the clinical outcomes from our groundbreaking SECURE-T2D and RADIANT trials, as well as the real-world outcomes we are seeing, especially with type 2 diabetes,' said Dr. Trang Ly, MBBS, FRACP, PhD, Insulet Senior Vice President and Chief Medical Officer. 'We are also looking forward to many conversations with healthcare providers about what the outcomes mean, with practical insights on how to optimize therapy.' Insulet shared results of the first large pivotal trial of Automated Insulin Delivery (AID) in type 2 diabetes (SECURE-T2D) at last year's ADA conference. In March, Insulet presented results of the first randomized controlled trial to assess the direct transition from multiple daily injections (MDI) to AID in adults and children with type 1 diabetes not meeting glycemic targets with injections (RADIANT). Presentations at ADA this week will provide richer insights into both trials and more. Conference Activities: Dr. Ly will lead a panel discussion, ' Setting the Standard with Omnipod 5: Remarkable Results with Unmatched Simplicity, ' on Sunday, June 22 from 10:15 – 11:00 AM CT in the conference product theater. She will be joined by Dr. Anders L. Carlson, MD, Associate Executive Director, International Diabetes Center, Director, HealthPartners Diabetes Program, and Associate Professor, University of Minnesota Medical School; Dr. Gregory Forlenza, MD, MS, Associate Professor of Pediatrics, Director of Pediatric Diabetes Technology Research, Barbara Davis Center for Diabetes at the University of Colorado Anschutz Medical Campus; and Dr. Emma Wilmot, MB ChB BSc (hons), PhD, FRCP, Associate Professor, University of Nottingham, Honorary Consultant Diabetologist, University Hospitals of Derby and Burton NHS Trust, Royal Derby Hospital UK. They will have an interactive conversation around several thought-provoking case studies designed to challenge conventional thinking and therapeutic approaches. Dr. Ly will also provide a high-level overview of Insulet's innovation roadmap. Additionally, on Saturday, June 21, there will be a Diabetes Learning Byte session, ' Go Beyond GLP-1 Therapy in Type 2 Diabetes with Omnipod 5,' from 11:00 AM – 11:20 AM CT at booth 927 with Davida F. Kruger, MSN, APN-BC, BC-ADM, Certified Nurse Practitioner, Henry Ford Health Division of Endocrinology, Diabetes, Bone and Mineral Disease; and Leslie Barrett, MS, RD, CDCES, Director of Medical Affairs, Insulet. Oral Presentations Friday, June 20, Session: 5:30 – 6:30 PM CT, Presentation 5:45 – 6:00 PM CT (W184A-D) 130-OR– Real-World Glycemic Outcomes in Adults with Type 2 Diabetes (T2D) Using the Omnipod 5 Automated Insulin Delivery (AID) System with Dr. Sean Oser Saturday, June 21, Session: 1:30 – 3:00 PM CT, Presentation 2:00 – 2:15 PM CT (W185A-D) 155-OR– Reduced Perceived Diabetes Distress with the Omnipod 5 Automated Insulin Delivery (AID) System in Adults with Type 2 Diabetes (T2D) – Analysis of the SECURE-T2D Study with Dr. Kristin Castorino Monday, June 23, Session: 1:30 – 3:00 PM CT, Presentation 2:45 – 3:00 PM CT (W183A) 314-OR– Improved Outcomes Across Baseline Time-in-Range Levels with the Omnipod 5 AID System Compared with Multiple Daily Injections (MDI) in Type 1 Diabetes (T1D): Analysis of the RADIANT Study with Dr. Emma Wilmot Poster Presentations The following poster presentations will be held from 12:30 – 1:30 PM CT in the Poster Hall (Hall F1) during the weekend. Saturday, June 21 [945-P] – Improved Glycemic Outcomes with the Omnipod 5 AID System in Adults with Type 2 Diabetes (T2D) Previously Using Basal without Bolus Insulin: Sub-analysis of the SECURE-T2D Study with Dr. Anders Carlson [937-P] – Successful Transition from Multiple Daily Injections (MDI) to Automated Insulin Delivery (AID): Real-world Glycemic Outcomes among People with Diabetes Using the Omnipod AID System with Dr. Grazia Aleppo [958-P] – Impact of Insulin Therapy Technology on Health-Related Quality of Life in Adults with Type 1 Diabetes: A Health Utility Study of Five Forms of Therapy with Colin Hopley, MPH, Insulet Sunday, June 22 [2011-LB] – iPhone App Adoption Improves Bolusing Frequency in Adolescents and Young Adults with Type 1 Diabetes (T1D): Insights from Real-World Omnipod ® 5 Automated Insulin Delivery (AID) System Use with Dr. Gregory Forlenza Booth Activities: Podcast recordings for Beyond the Bolus, Within Range will be conducted from Insulet's booth (1218). Also, a Baird hosted webcast, ' ADA Recap Interview with Dr. Trang Ly, ' will be facilitated by Sr. Research Analyst, Jeff Johnson. This will take place on Monday, June 23, at 11:00 AM CT. The interview will feature a recap of highlights, new clinical data, and updates from ADA. A link to the webcast will be available on the Investor Relations section of the Company's website at under 'Events and Presentations,' and will be archived for future replay. Insulet will bring immersive booth experiences that showcase how Omnipod 5 is transforming diabetes management. Attendees can engage in hands-on demonstrations led by clinical experts, exploring optimization techniques that support better outcomes. Attendees can also play an educational trivia game to learn how Omnipod 5 brings a whole new level of simplicity and convenience for mealtime insulin dosing. Insulet will also be distributing a new comic book to celebrate representation for the diabetes community. Dyasonic: Sound of Strength featuring a hero with type 1 diabetes. To access the comic book and related materials go to About Insulet Corporation: Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit: and ©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. All other trademarks are the property of their respective owners. The use of third-party trademarks does not constitute an endorsement or imply a relationship or other affiliation.
Yahoo
7 days ago
- Business
- Yahoo
Truist starts on diabetes device makers, sees glucose monitor, insulin pump growth
-- Truist Securities launched coverage on four diabetes technology companies, saying there is a long-term growth potential for continuous glucose monitors (CGM) and insulin pumps amid rising adoption in both type 1 and type 2 diabetes patients. The firm started Dexcom (NASDAQ:DXCM), Insulet (NASDAQ:PODD), and Beta Bionics with Buy ratings, while initiating Tandem Diabetes Care (NASDAQ:TNDM) at Hold. Truist already covers Medtronic's diabetes business, which it rates 'Hold.' Truist said the diabetes device sector is positioned for double-digit growth over the next several years, driven by expanding use in underpenetrated global markets and a shift toward more patient-centric care. Survey feedback from physicians suggested stronger adoption of pumps and CGMs in type 2 diabetes, particularly among patients using insulin. Among the large-cap names, the firm favored Dexcom and Insulet, citing strong profitability and leadership in the growing CGM and patch pump segments. While Truist said that Insulet's recent CEO change may introduce some near-term uncertainty, it said the company's growth trajectory remains intact. Dexcom, which has faced concerns following mid-2024 execution missteps and rising competition from Abbott's Libre system, still offers a favorable risk-reward, Truist said, pointing to a lower relative valuation and catalysts such as guideline updates and expanding reimbursement for type 2 diabetes. In the small-cap space, Truist preferred Beta Bionics over Tandem. It noted both firms face challenges in the slower-growing durable pump market but said Beta Bionics' iLet system has a potential ease-of-use advantage and a head start in transitioning to more profitable pharmacy distribution channels. Regarding potential volatility in shares of both Beta Bionics and Tandem, Truist said the broader diabetes device market remains one of the most attractive growth areas in medtech, supported by technology innovation, evolving reimbursement, and increased patient engagement. Related articles Truist starts on diabetes device makers, sees glucose monitor, insulin pump growth Boeing Commercial Airplanes head meets Air India chairman after fatal 787 crash Forward Air stock surges on report PE firms express acquisition interest
Yahoo
10-06-2025
- Business
- Yahoo
PODD Q1 Earnings Call: Insulet Highlights New Leadership and Strong Omnipod Adoption
Insulin delivery company Insulet Corporation (NASDAQ:PODD) beat Wall Street's revenue expectations in Q1 CY2025, with sales up 28.8% year on year to $569 million. On top of that, next quarter's revenue guidance ($608.2 million at the midpoint) was surprisingly good and 5.5% above what analysts were expecting. Its non-GAAP profit of $1.02 per share was 29.7% above analysts' consensus estimates. Is now the time to buy PODD? Find out in our full research report (it's free). Revenue: $569 million vs analyst estimates of $543 million (28.8% year-on-year growth, 4.8% beat) Adjusted EPS: $1.02 vs analyst estimates of $0.79 (29.7% beat) Revenue Guidance for Q2 CY2025 is $608.2 million at the midpoint, above analyst estimates of $576.3 million Operating Margin: 15.6%, up from 12.9% in the same quarter last year Constant Currency Revenue rose 29.8% year on year (22.8% in the same quarter last year) Market Capitalization: $21.51 billion Insulet's first quarter results reflected continued momentum in automated insulin delivery, driven by robust demand for the Omnipod 5 platform across both U.S. and international markets. Management cited commercial execution, with CEO Ashley McEvoy emphasizing the company's unique positioning at the intersection of consumer health and medical technology. The team pointed to growth in new customer starts for both type 1 and type 2 diabetes, with over 85% of U.S. new starts coming from multiple daily injection (MDI) users and more than 30% from type 2 patients. CFO Ana Chadwick highlighted operational improvements and manufacturing efficiencies, resulting in gross margin expansion and stable retention rates, especially following the launch of Omnipod 5 in new international markets. Looking ahead, Insulet's guidance for the next quarter and the full year is underpinned by ongoing investments in product innovation, expanded commercial reach, and international market launches. CEO Ashley McEvoy stated that the company's priorities remain focused on advancing technology, driving growth in both type 1 and type 2 diabetes segments, and expanding Omnipod 5's global footprint. She noted, 'Our strategy is intact. We will continue to drive robust growth and do so profitably on a global scale.' Management also discussed the impacts of tariffs and supply chain dynamics, but expressed confidence in maintaining margin expansion through efficiency gains and scale. Omnipod 5 launches in new countries and continued direct-to-consumer marketing are expected to further support growth. Management attributed the quarter's performance to strong Omnipod 5 adoption, commercial investments, and operational discipline across manufacturing and supply chain. Type 2 diabetes expansion: The U.S. launch of Omnipod 5 for type 2 diabetes contributed to over 30% of new customer starts in the quarter, supported by a recently expanded sales force and targeted direct-to-consumer advertising. International growth momentum: International markets saw Omnipod 5 launches in Canada and Switzerland, bringing the total to 13 countries, with further expansion planned in the Middle East. International new customer starts increased sequentially, driven by new sensor integrations and customer upgrades. Advances in automation and manufacturing: Investments in advanced automation and the ramp-up of the Malaysia facility were cited as key drivers of gross margin expansion. Management stated the Malaysia site is on track to be accretive to margins by the third quarter. Direct-to-consumer (DTC) strategy: Higher conversion rates from DTC efforts are bringing more interested patients into the Omnipod ecosystem. Management highlighted more efficient advertising spend and improved lead conversion. Stable retention and utilization: Retention rates remained steady in the U.S. and improved internationally with Omnipod 5 adoption. Utilization metrics for new type 2 users closely mirrored those for type 1, with only slightly higher attrition, as expected by management. Insulet expects continued growth, supported by Omnipod 5 adoption, expansion into new markets, and operational efficiencies, while monitoring potential risks from tariffs and international launches. Broader type 2 adoption: Management is prioritizing growth in the U.S. type 2 diabetes segment, focusing on expanding prescriber reach through a larger sales force and leveraging clinical data to promote adoption. Early results show increased prescription activity among health care providers, and management believes the market could double or triple in the coming years, though the exact pace remains uncertain. International market expansion: The company is launching Omnipod 5 in new regions, including recent entries into Canada and Switzerland and planned launches in the Middle East. Management expects international growth to be driven primarily by volume as more markets upgrade from earlier Omnipod versions, with ongoing efforts to adapt U.S. commercial strategies to fit international contexts. Margin management amid tariffs: Insulet forecasts stable gross and operating margins, despite a projected 50 basis point impact from tariffs related to China. Investments in automation and diversified manufacturing are expected to offset these pressures, and the company is raising its gross margin outlook while maintaining ongoing R&D and commercial investments. In the coming quarters, the StockStory team will be watching (1) whether Insulet can maintain momentum in type 2 diabetes adoption and expanded health care provider engagement, (2) the progress and outcomes of new international Omnipod 5 launches—particularly in the Middle East, and (3) the impact of manufacturing scale-ups and automation on gross margins. Developments in direct-to-consumer strategies and tariff management will also be important markers of execution. Insulet currently trades at a forward P/E ratio of 69.1×. At this valuation, is it a buy or sell post earnings? See for yourself in our full research report (it's free). Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
